CLINICAL GUIDELINE: PART III: Screening for Prostate Cancer. Ann Intern Med. 1997;126:480-484. doi: 10.7326/0003-4819-126-6-199703150-00011
Download citation file:
Published: Ann Intern Med. 1997;126(6):480-484.
Prostate cancer, which caused an estimated 40 000 deaths and substantial aggregate illness in 1995, is now the most commonly diagnosed type of cancer among men in the United States . However, whether early detection of this disease generally does more good than harm is a matter of controversy [2-8]. As a result, conflicting recommendations have been issued by various professional organizations [6-8]. The debate is fueled by the absence of evidence from controlled studies showing that screening reduces mortality related to prostate cancer. Moreover, the degree to which radical prostatectomy or radiation therapy for clinically localized prostate cancer improves life expectancy, aggregate morbidity, or overall quality of life for the typical patient is uncertain. Several ongoing trials of early detection and treatment should eventually answer these questions [9-12]. However, because of the slow progression of most cases of prostate cancer, the results of these trials are not expected for at least a decade. In addition, differences among available professional recommendations appear to derive largely from differences in the level of evidence that each group requires to advocate screening [6-813, 14].
Learn more about subscription options.
Register Now for a free account.
Hematology/Oncology, Prostate Cancer, Cancer Screening/Prevention, Prevention/Screening.
Results provided by:
Copyright © 2016 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only